PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 4, 2022The Lancet Oncology531 citationsOpen Access

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

RKRobin Kate KelleyLRLorenza RimassaACAnn‐Lii Cheng

Key Points

Key points are not available for this paper at this time.

Abstract

Exelixis and Ipsen.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kelley et al. (2022) studied this question.

synapsesocial.com/papers/69d968a394760e72e6a3c5d3https://doi.org/10.1016/s1470-2045(22)00326-6
Ask AI
Helpful
Bookmark
Share
View Full Paper